Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.
Publication Type:
Journal ArticleSource:
AIDS (London, England), Volume 25, Issue 2, p.153-8 (2011)Keywords:
2011, Adenoviridae Infections, Adenoviruses, Human, Adult, Africa, AIDS Vaccines, Antibodies, Neutralizing, Case-Control Studies, Female, Genetic Vectors, HIV Seropositivity, HIV-1, Humans, Male, Risk Assessment, South America, United States, Vaccine and Infectious Disease DivisionAbstract:
adenoviruses are among the most promising vectors for the development of an HIV vaccine. The results of the phase IIB study of the adenovirus serotype 5-based Merck Trivalent HIV vaccine have raised the concern that serological immunity to adenovirus serotype 5 (Ad5) could be linked to HIV acquisition risk in high-risk individuals. We examined the association between adenovirus serostatus and the rate of incident HIV infection in populations at elevated risk of HIV acquisition.
Doing Business with Arnold Library
Weintraub Building, B1-010
(206) 667-4314
library@fredhutch.org
More About Arnold Library
Quick Links
- ILLiad/ILL Form
- Journals List
- Ovid - Medline
- Web of Science
- Pubmed
- Libguides
- Library Catalog
- Researcher Profiles
- Library Affiliations & Memberships
- Fred Hutch Papers (Intranet)